Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Teleflex (TFX) stock in plain English

Free brief · no signupStart here
TFXPublished Nov 18, 2026
Teleflex Incorporated
Healthcare · Medical Instruments & Supplies
Manufactures specialized disposable instruments and catheters for critical care, surgical procedures, and cardiac surgery.
Assets:
30 production facilitiesOperates cleanroom and device assembly plants across North America, Europe, and Asia.
Arrow vascular lineSupplies central venous catheters and arterial lines to emergency departments.
UroLift urology systemProvides minimally invasive implants to treat benign prostatic hyperplasia in outpatient clinics.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

73
OPS ScoreOperating finances
Latest quote
-1.48%$163.40
$6.48B
19.9×
$2.26B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 18, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was TFX. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Teleflex (TFX) do?

Teleflex Incorporated (TFX) is a U.S.-listed company in Healthcare (Medical Instruments & Supplies). What it does: Manufactures specialized disposable instruments and catheters for critical care, surgical procedures, and cardiac surgery. It designs specialized single-use medical devices primarily for intensive care units and operating rooms. It is worth $6.48B on the market and sold $2.26B over the last year.

Market cap
$6.48B
P/E ratio
19.9×
Annual sales
$2.26B
Sector
Healthcare
Industry
Medical Instruments & Supplies
Brief updated
Nov 18, 2026

Brands and businesses behind TFX

  • Arrow: Manufactures vascular access catheters and related insertion kits for hospital critical care units.
  • UroLift: Sells minimally invasive permanent implant systems used by urologists to treat enlarged prostate conditions.
  • QuikClot: Produces chemically treated hemostatic gauze pads and dressings that accelerate blood clotting for trauma wounds.
  • LMA: Supplies supraglottic airway management masks used by anesthesiologists during surgical procedures.
  • Rusch: Sells endotracheal tubes, urinary drainage bags, and catheters to hospitals for patient care.

TFX’s flags, in plain English

Each flag is a number from Teleflex’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.

Wide Gross Margin

Gross margin of 65.3% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Growth vs Price

The price looks reasonable for how fast it is growing. The price looks reasonable for how fast its profits are growing.

Stupid Cash

Can pay this year's bills 2 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Growth Cooling

Sales growth slowed to -4.7% a year over 5 years. Sales are growing more slowly than before, which makes the current share price harder to justify.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about TFX

How big is Teleflex?

Teleflex’s market cap is $6.48B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $2.26B: what customers paid the company over the last year, before any costs.

What is TFX’s P/E ratio?

TFX’s P/E ratio is 19.9×. Investors pay about 19.9 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with TFX?

Sales of the UroLift system face pressure from competing office-based urology treatments and changing payer reimbursement policies. That is one risk on Teleflex’s card. Its first risk flag is Growth Cooling, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Teleflex’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. TFX’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card